Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Empowering Reproductive Healthcare: Reflections and Calls to Action From the 2024 American Society of Reproductive Immunology (ASRI) Meeting Policy Advocacy Session
Powell, Anna , Weng, Jessica , Jones, Brittany R., Johnson, Ann, Bonney, Elizabeth A. , Mysorekar, Indira U. , Mysorekar, Indira U , Weng, Jessica , Hesse, Lauren, Johnson, Ann

Mayo Clinic

American Journal of Reproductive Immunology | October 16, 2024 | Volume: 92 | Issue: 4 | Pages: No page available

10.1111/aji.13943 | PMID 39412442 Get It

Long-term Outcomes of Complete Tears of the Distal Biceps Tendon: An Analysis of Surgical Management at a Median Follow-up of 14.7 Years
Till, Sara E., Reinholz, Anna K., Johnson, Adam C. , Sanchez-Sotelo, Joaquin, Camp, Christopher L. , Tagliero, Adam J. , Pan, Xuankang , Sánchez‐Sotelo, Joaquín , Barlow, Jonathan D.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | October 14, 2024 | Volume: 12 | Issue: 10 | Pages: No page available

10.1177/23259671241283787 | PMID 39421041 Get It

Background: Surgical repair of full thickness biceps tears has demonstrated adequate outcomes in short and mid-term studies. However, data on the long-term outcomes of full thickness distal biceps injuries and their treatment are currently lacking. Purpose/Hypothesis: The purpose of this study was to report on patient demographics, injury characteristics, and long-term outcomes for patients with full-thickness distal biceps tears. It was hypothesized that complete distal biceps tears managed operatively would demonstrate robust clinical success at long-term follow-up. Study Design: Case series; Level of evidence, 4. Methods: Patients with magnetic resonance imaging–confirmed, complete distal biceps tendon rupture sustained between 1996 and 2016 were identified. Patients were cross-referenced with a regional geographic database. Results: A total of 66 patients (3 female, 63 male) with a median age of 50.8 years (IQR, 41.5-60.4) and a median clinical follow-up of 14.7 years (IQR, 9.6-17.9 years) were included. Patients who sustained a full-thickness distal biceps tendon tear were likely to be in their early 50s, male, right-hand dominant, current/former smokers, and laborers with a history of traumatic injury during an intentional movement. Most of these patients had pain and supination weakness but no loss of range of motion. All included tears were treated operatively. At final follow-up, patients maintained a majority of near-normal range of motion (median total arc of flexion/extension 140° and supination/pronation 80°), excellent elbow flexion strength (91% of patients had full strength), and adequate elbow supination strength (76% of patients had full strength). The overall complication rate was 24%, with 16 out of 66 patients experiencing some type of complication between infection, rerupture, heterotopic ossification, reoperation, and nerve complications. Overall return to work was 98%, and 85% of those who returned to work did so without restrictions. Conclusion: Complete tears of the distal biceps were most common in patients 50 years of age, male sex, right-hand dominant, and current/former smokers. The most common profession was laborer, and injuries were primarily traumatic in nature during intentional activity. Patients managed operatively demonstrated high rates of success at long-term follow-up with respect to elbow function and clinical outcomes.
Association Between Dietary Patterns and Subgingival Microbiota: Results From the Oral Infections, Glucose Intolerance, and Insulin Resistance Study (ORIGINS)
Molinsky, Rebecca , Johnson, Abigail J. , Marotz, Lisa, Roy, Sumith , Bohn, Bruno , Goh, Charlene Enhui , Chen, Ching‐Yuan, Paster, Bruce J. , Genkinger, Jeanine M. , Jacobs, David R. , Demmer, Ryan T. , Molinsky, Rebecca L , Goh, Charlene E , Genkinger, Jeanine , Papapanou, Panos N , Demmer, Ryan T , Jacobs, David R , Knight, Rob

Mayo Clinic

Journal of Clinical Periodontology | October 12, 2024 | Volume: 52 | Issue: 1 | Pages: 2-15

10.1111/jcpe.14067 | PMID 39394967 Get It

ABSTRACTObjectiveTo study the association between dietary patterns and subgingival microbiota.MethodsParticipants (n = 651) who were enrolled in the Oral Infections, Glucose Intolerance, and Insulin Resistance Study (ORIGINS) with subgingival plaque sampling (n = 890 plaques) and a dietary assessment were included. 16S rRNA gene amplicon sequences of subgingival plaque from sites with either probing depth <4 or ≥4 mm were processed separately and used to obtain α‐diversity metrics (Faith, Shannon, Simpson, Observed) and taxa ratios (Red Complex to Corynebacterium [RCLR], Treponema to Corynebacterium [TCLR], and Treponema to Neisseria [TNLR]). Food frequency questionnaires (FFQs) were processed to calculate Alternate Healthy Eating Index (AHEI) and A Priori Diet Quality Score (APDQS) scores. Mixed regression models examined the mean levels of microbial metrics across quartiles of diet quality. Means ± standard errors are reported along with p‐values.ResultsIn multivariable models assessing the association between diet scores and α‐diversity metrics, higher AHEI values were significantly associated with lower Faith (p‐value = 0.01) and Observed (p‐value = 0.04) diversity values; similar findings were observed for APDQS (p‐value = 0.01, p‐value = 0.04). In multivariable models assessing the association between diet scores (AHEI and APDQS) and taxa ratios (RCLR, TCLR and TNLR), as the AHEI quartile increased, all taxa ratios decreased significantly as follows: −1.06 ± 0.093 in Q1 to −1.34 ± 0.099 in Q4 (RCLR), −0.43 ± 0.077 in Q1 to −0.64 ± 0.083 in Q4 (TCLR) and −0.09 ± 0.083 in Q1 to −0.38 ± 0.089 in Q4 (TNLR), respectively. In contrast, as the APDQS quartiles increased, only TNLR decreased significantly from −0.08 ± 0.085 in Q1 to −0.34 ± 0.091 in Q4.ConclusionDiets rich in fruits, vegetables, whole grains and other nutritionally rich plant foods are associated with lower oral microbial diversity and favourable ratios of pathogenic to commensal microbiota.
The journey to building a diverse, equitable, and inclusive American Medical Informatics Association
Bright, Tiffani J , Walk, Oliver J. Bear Don’t , Johnson, Cheyenne , Petersen, Carolyn , Martin, Krista, Walters-Threat, Lois, Craven, Catherine K. , Lucero, Robert , Bear Don't Walk Iv, Oliver J , Johnson, Carl Erwin , Craven, Catherine K , Rizvi, Rubina F , Petersen, Carolyn , Dykes, Patricia C. , Johnson, Kevin B. , Jackson, Gretchen Purcell

Mayo Clinic

Journal of the American Medical Informatics Association | October 12, 2024 | Volume: 32 | Issue: 1 | Pages: 3-8

10.1093/jamia/ocae258 | PMID 39394736 Get It

Abstract Objective The American Medical Informatics Association (AMIA) Task Force on Diversity, Equity, and Inclusion (DEI) was established to address systemic racism and health disparities in biomedical and health informatics, aligning with AMIA’s mission to transform healthcare. AMIA’s DEI initiatives were spurred by member voices responding to police brutality and COVID-19’s impact on Black/African American communities. Materials and Methods The Task Force, consisting of 20 members across 3 groups aligned with AMIA’s 2020-2025 Strategic Plan, met biweekly to develop DEI recommendations with the help of 16 additional volunteers. These recommendations were reviewed, prioritized, and presented to the AMIA Board of Directors for approval. Results In 9 months, the Task Force (1) created a logic model to support workforce diversity and raise AMIA’s DEI awareness, (2) conducted an environmental scan of other associations’ DEI activities, (3) developed a DEI framework for AMIA meetings, (4) gathered member feedback, (5) cultivated DEI educational resources, (6) created a Board nominations and diversity session, (7) reviewed the Board’s Strategic Planning for DEI alignment, (8) led a program to increase diversity at the 2020 AMIA Virtual Annual Symposium, and (9) standardized socially-assigned race and ethnicity data collection. Discussion The Task Force proposed actionable recommendations that focused on AMIA’s role in addressing systemic racism and health equity, helping the organization understand its member diversity. Conclusion This work supported marginalized groups, broadened the research agenda, and positioned AMIA as a DEI leader while reinforcing the need for ongoing transformation within informatics.
An Updated Evaluation of the Management of Nerve Gaps: Autografts, Allografts, and Nerve Transfers
Johnson, Anna Rose , Said, Abdullah M., Acevedo, Jesús F. , Taylor, R. W., Wu, Kitty Y. , Ray, Wilson Z. , Patterson, J. Megan M. , Mackinnon, Susan E., Mackinnon, Susan E. , Wu, Kitty, Acevedo, Jesus

Mayo Clinic

Seminars in Neurology | October 11, 2024 | Volume: 45 | Issue: 01 | Pages: 157-175

10.1055/s-0044-1791665 | PMID 39393799 Get It

AbstractWithin the past decade, there have been multiple innovations in the field of nerve surgery. In this review, we highlight critical changes and innovations that have helped advance the field and present opportunities for further study. This includes the modification and clarification of the classification schema for nerve injuries which informs prognosis and treatment, and a refined understanding and application of electrodiagnostic studies to guide patient selection. We provide indications for operative intervention based on this nerve injury classification and propose strategies best contoured for varying injury presentations at differing time points. Lastly, we discuss new developments in surgical techniques and approaches based on these advancements.
Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas After Liver Transplantation
Busebee, Bradley , Chin, Jerry Yung‐Lun , Mara, Kristin C. , Johnson, Brad , Takahashi, Naoki , Majumder, Shounak , Watt, Kymberly D. , Busebee, Brad , Mara, Kristin, Majumder, Shounak , Mara, Kristin C , Takahashi, Naoki , Johnson, Brad

Mayo Clinic

Clinical Transplantation | October 4, 2024 | Volume: 38 | Issue: 10 | Pages: No page available

10.1111/ctr.15431 | PMID 39365117 Get It

ABSTRACTBackgroundIntraductal papillary mucinous neoplasms (IPMNs) are the most commonly identified pancreatic cystic neoplasms. Incidentally detected IPMNs are common among liver transplant recipients. The risk of IPMN progression to pancreatic cancer in transplant recipients and the impact of immunosuppression on the risk of malignant transformation of IPMN are unclear.MethodsIn this retrospective study of consecutive liver transplant recipients across Mayo Clinic over a 13‐year period, patients were assessed for possible IPMN by automated chart review. Pancreatic cystic lesions were characterized as suspected IPMNs based on imaging criteria. Cox proportional hazards models were used to determine the association between IPMN progression (the development of cancer or worrisome features) and clinical and immunosuppression regimen characteristics.ResultsOf 146 patients with suspected IPMNs, progression occurred in 7 patients (2 cases of IPMN‐associated cancer and 5 cases of worrisome features) over an average follow‐up of 66.6 months. Immunosuppression type, medication number, and tacrolimus trough levels were not associated with IPMN progression (p > 0.05). Combined kidney and liver transplantation (p = 0.005) and pretransplant cholangiocarcinoma (p = 0.012) were associated with IPMN progression.ConclusionIPMN progression is rare after liver transplantation even over an extended follow‐up period. The findings were notable for the absence of an association between IPMN progression and immunosuppression regimen. Larger studies are needed given the low incidence.
A new prognostic model in patients with recurrent or metastatic head and neck cancer treated with chemotherapy: An analysis of ECOG-ACRIN E1305.
Johnson, Jennifer M. , Forastiere, Arlene A. , Argiris, Athanassios E. , Flamand, Yael , Savvides, P. , Li, Shuli , Burtness, Barbara

Mayo Clinic

Journal of Clinical Oncology | October 3, 2024 | Volume: 40 | Issue: 16_suppl | Pages: 6026-6026

10.1200/jco.2022.40.16_suppl.6026 Get It

6026 Background: We examined a large patient dataset based on E1305, a completed phase III randomized trial of platinum-based chemotherapy with or without bevacizumab (Argiris et al. JCO 2019), to evaluate prognostic factors in the first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RM SCCHN) and expand on our previous observations in cooperative group trials (Argiris et al. Cancer 2004). Methods: All 403 patients enrolled in E1305 were analyzed. Overall survival (OS) was the outcome of interest. Clinical and tumor characteristics were examined using Cox proportional hazards models. Variables which were significant in the univariate setting at a level of ≤ 0.10 were included in a multivariable model, and backwards selection was performed (threshold of p ≤ 0.05). The final multivariable model was then applied to the two treatment arms, separately. Variables for which the hazards ratio (HR) within an arm was more than 10% different than that for the whole cohort, were removed from the final cohort model. Results: The median OS in the whole study cohort was 11.8 months. A prognostic score model for OS was built, using the 4 independent prognostic factors identified in the multivariable model: ECOG performance status (1 vs 0), prior radiation, primary region (non-oropharynx vs oropharynx), and metastatic disease bone or liver (vs other sites/no metastases). Prognostic score was dichotomized (0-2 and > 2). Patients with 0-2 risk factors (n = 249) had a median OS of 15.2 months (90% CI: 13.8, 18.1), while patients with > 2 risk factors (n = 154) had a median OS of 7.6 months (90% CI: 6.5, 9.3); HR of 2.14 (95% CI: 1.73, 2.66), p < 0.0001. Compared to our previous 5-factor model from analysis of older trials in a similar setting, the variable “bone/liver metastasis” is new, but “tumor cell differentiation” and “weight loss” were not significant and not included in the new model for OS. Conclusions: The new proposed model includes 4 prognostic factors for OS (performance status, primary site, prior radiation, presence of bone/liver metastasis) in the first-line treatment of RM SCCHN.
Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma
Buras, Matthew R., Carter, Rickey E. , Joyner, Michael J. , Bloch, Evan M. , Henderson, Jeffrey P. , Senefeld, Jonathon W. , Wright, R. Scott , Carter, Rickey E , Joyner, Michael J , Henderson, Jeffrey P , Shoham, Shmuel , Sullivan, David J , Casadevall, Arturo , Senefeld, Jonathon W , Dragotakes, Quigly , Johnson, Patrick W. , Gebo, Kelly A , Hanley, Daniel F. , Pirofski, Liise‐anne , Shoham, Shmuel , Tobian, Aaron A.R. , Wiggins, Chad C. , Paneth, Nigel , Sullivan, David , Casadevall, Arturo

Mayo Clinic

Proceedings of the National Academy of Sciences | October 1, 2024 | Volume: 121 | Issue: 41 | Pages: No page available

10.1073/pnas.2414957121 | PMID 39352932 Get It

In the Spring of 2020, the United States of America (USA) deployed COVID-19 convalescent plasma (CCP) to treat hospitalized patients. Over 500,000 patients were treated with CCP during the first year of the pandemic. In this study, we estimated the number of actual inpatient lives saved by CCP treatment in the United States of America based on CCP weekly use, weekly national mortality data, and CCP mortality reduction data from meta-analyses of randomized controlled trials and real-world data. We also estimate the potential number of lives saved if CCP had been deployed for 100% of hospitalized patients or used in 15 to 75% of outpatients. Depending on the assumptions modeled in stratified analyses, we estimated that CCP saved between 16,476 and 66,296 lives. The CCP ideal use might have saved as many as 234,869 lives and prevented 1,136,133 hospitalizations. CCP deployment was a successful strategy for ameliorating the impact of the COVID-19 pandemic in the USA. This experience has important implications for convalescent plasma use in future infectious disease emergencies.
Fueling the Firefighter and Tactical Athlete with Creatine: A Narrative Review of a Key Nutrient for Public Safety
Gonzalez, Drew E. , Forbes, Scott C. , Zapp, Annette , Jagim, Andrew R. , Luedke, Joel, Root, Alexandria, Gil, Adriana , Johnson, Sarah E. , Coles, Macilynn E., Brager, Allison J. , Sowinski, Ryan , Candow, Darren G. , Kreider, Richard B. , Jagim, Andrew R , Sowinski, Ryan J , Kreider, Richard B , Forbes, Scott C , Dickerson, Broderick L.

Mayo Clinic

Nutrients | September 30, 2024 | Volume: 16 | Issue: 19 | Pages: 3285

10.3390/nu16193285 | PMID 39408252 Get It

Background/Objectives: Firefighters, tactical police officers, and warriors often engage in periodic, intermittent, high-intensity physical work in austere environmental conditions and have a heightened risk of premature mortality. In addition, tough decision-making challenges, routine sleep deprivation, and trauma exacerbate this risk. Therefore, identifying strategies to bolster these personnel’s health and occupational performance is critical. Creatine monohydrate (CrM) supplementation may offer several benefits to firefighters and tactical athletes (e.g., police, security, and soldiers) due to its efficacy regarding physical performance, muscle, cardiovascular health, mental health, and cognitive performance. Methods: We conducted a narrative review of the literature with a focus on the benefits and application of creatine monohydrate among firefighters. Results: Recent evidence demonstrates that CrM can improve anaerobic exercise capacity and muscular fitness performance outcomes and aid in thermoregulation, decision-making, sleep, recovery from traumatic brain injuries (TBIs), and mental health. Emerging evidence also suggests that CrM may confer an antioxidant/anti-inflammatory effect, which may be particularly important for firefighters and those performing tactical occupations exposed to oxidative and physiological stress, which can elicit systemic inflammation and increase the risk of chronic diseases. Conclusions: This narrative review highlights the potential applications of CrM for related tactical occupations, with a particular focus on firefighters, and calls for further research into these populations.
Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Lemaı̂tre, F. , Barten, Markus J. , Bergan, Stein , Shipkova, Maria , Vinks, Sander, Wieland, Eberhard , Bornemann-Kolatzki, Kirsten , Brunet, Mercè , Winter, Brenda C. M. de , Ito, Taihei, Johnson‐Davis, Kamisha L. , Kunicki, Paweł K. , Lawson, Roland , Lloberas, Núria , Marquet, Pierre , Millán, Olga , Mizuno, Tomoyuki , Noceti, Ofelia , Oellerich, Michael , Pattanaik, Smita , Seger, Christoph , Schaik, Ron HN van , Venkataramanan, Raman , Walson, Phil, Woillard, Jean‐Baptiste , Langman, Loralie J., Masuda, Satohiro , Lemaitre, Florian, Gelder, Teun van , Vinks, Sander, Dieterlen, Maja‐Theresa , Elens, Laure , Moes, Dirk Jan A. R. , Pawiński, Tomasz , Walson, Philip D.

Mayo Clinic

Therapeutic Drug Monitoring | September 27, 2024 | Volume: 47 | Issue: 1 | Pages: 4-31

10.1097/ftd.0000000000001250 | PMID 39331837 Get It

Abstract: The Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology established the second consensus report to guide therapeutic drug monitoring (TDM) of everolimus (EVR) and its optimal use in clinical practice 7 years after the first version was published in 2016. This version provides information focused on new developments that have arisen in the last 7 years. For the general aspects of the pharmacology and TDM of EVR that have retained their relevance, readers can refer to the 2016 document. This edition includes new evidence from the literature, focusing on the topics updated during the last 7 years, including indirect pharmacological effects of EVR on the mammalian target of rapamycin complex 2 with the major mechanism of direct inhibition of the mammalian target of rapamycin complex 1. In addition, various concepts and technical options to monitor EVR concentrations, improve analytical performance, and increase the number of options available for immunochemical analytical methods have been included. Only limited new pharmacogenetic information regarding EVR has emerged; however, pharmacometrics and model-informed precision dosing have been constructed using physiological parameters as covariates, including pharmacogenetic information. In clinical settings, EVR is combined with a decreased dose of calcineurin inhibitors, such as tacrolimus and cyclosporine, instead of mycophenolic acid. The literature and recommendations for specific organ transplantations, such as that of the kidneys, liver, heart, and lungs, as well as for oncology and pediatrics have been updated. EVR TDM for pancreatic and islet transplantation has been added to this edition. The pharmacodynamic monitoring of EVR in organ transplantation has also been updated. These updates and additions, along with the previous version of this consensus document, will be helpful to clinicians and researchers treating patients receiving EVR.